Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-002 in Amyotrophic Lateral Sclerosis
NCT07660614Phase 2Recruiting
- Sponsor
- Leal Therapeutics
- Start
- Apr 2026
- Primary completion
- Jun 2031
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing LTX-002 with Placebo (aCSF) (2 arms). Primary endpoints: Safety and Tolerability (Adverse Events) at Day 169, Safety and Tolerability (Clinical Laboratory Tests) at Day 169 and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
LTX-002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07660614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660614.